Related Experiment Video
Updated: Jun 26, 2026
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
Phospholipase A2 inhibitor-loaded micellar nanoparticles attenuate inflammation and mitigate osteoarthritis
Yulong Wei1,2,3, Lesan Yan1, Lijun Luo1,4
1Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Treating osteoarthritis (OA) remains a major clinical challenge. Despite recent advances in drug discovery and development, no disease-modifying drug for knee OA has emerged with any notable clinical success, in part, due to the lack of valid and responsive therapeutic targets and poor drug delivery within knee joints. In this work, we show that the amount of secretory phospholipase A2 (sPLA2) enzyme increases in the articular cartilage in human and mouse OA cartilage tissues. We hypothesize that the inhibition of sPLA2 activity may be an effective treatment strategy for OA. To develop an sPLA2-responsive and nanoparticle (NP)-based interventional platform for OA management, we incorporated an sPLA2 inhibitor (sPLA2i) into the phospholipid membrane of micelles. The engineered sPLA2i-loaded micellar NPs (sPLA2i-NPs) were able to penetrate deep into the cartilage matrix, prolong retention in the joint space, and mitigate OA progression. These findings suggest that sPLA2i-NPs can be promising therapeutic agents for OA treatment.
Insights
Secretory phospholipase A2 (sPLA2) enzyme levels rise in osteoarthritis (OA) cartilage. Inhibiting sPLA2 with novel nanoparticles (sPLA2i-NPs) shows promise for treating knee OA by improving drug delivery and reducing disease progression.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Osteoarthritis Research
Background:
- Osteoarthritis (OA) treatment faces challenges due to a lack of effective disease-modifying drugs and poor drug delivery to knee joints.
- Secretory phospholipase A2 (sPLA2) enzyme levels are elevated in human and mouse OA cartilage, suggesting its potential role in OA pathogenesis.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting sPLA2 activity for OA treatment.
- To develop an sPLA2-responsive nanoparticle (NP) platform for enhanced OA management.
Main Methods:
- Engineered sPLA2 inhibitor (sPLA2i)-loaded micellar NPs (sPLA2i-NPs) by incorporating sPLA2i into the phospholipid membrane.
- Evaluated NP penetration into cartilage matrix, joint retention, and mitigation of OA progression in relevant models.
Main Results:
- The developed sPLA2i-NPs demonstrated deep penetration into the cartilage matrix.
- These NPs exhibited prolonged retention within the joint space.
- sPLA2i-NPs effectively mitigated OA progression, indicating therapeutic efficacy.
Conclusions:
- Elevated sPLA2 in OA cartilage presents a viable therapeutic target.
- sPLA2i-loaded NPs offer a promising strategy for targeted drug delivery and OA treatment.
- The developed sPLA2i-NP platform shows potential as a novel therapeutic agent for managing knee OA.
